Von Eschenbach Promotes Behind-The-Counter Drug Class

FDA and industry should immediately begin pursuing the development of a regulatory process for a behind-the-counter class of drugs, FDA Commissioner Andrew C. von Eschenbach, M.D., told OTC industry executives March 16